Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as a tablet for oral use. It is indicated for the treatment of chronic myeloid leukemia in adult patients.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib targets the BCR‑ABL tyrosine‑kinase pathway and is employed in chronic myeloid leukemia therapy. - Chronic myeloid leukemia (chronic phase): Reduces malignant cell proliferation and improves survival in adult patients. - Chronic myeloid leukemia (accelerated phase): Helps achieve hematologic and cytogenetic responses when disease progresses. - Chronic myeloid leukemia (blast phase): Provides a therapeutic option for patients with advanced disease resistant to prior therapy.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Fatigue: generalized tiredness. - Elevated liver enzymes: mild transaminase increase. - Myalgia: muscle aches.

Serious or Rare Side Effects: - Cardiovascular events: including arterial occlusion or ischemia. - Pancreatitis: inflammation of the pancreas. - Severe hepatotoxicity: marked liver injury. - QT interval prolongation: potential cardiac arrhythmia. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hyperglycemia: significant rise in blood glucose levels.

Patients should be monitored for specific safety concerns before and during therapy. - Cardiac assessment: evaluate baseline cardiovascular risk and monitor for ischemic events. - Hepatic function: check liver enzymes regularly and adjust therapy if significant elevation occurs. - Electrolyte balance: monitor potassium and magnesium to reduce QT prolongation risk. - Blood glucose: assess glucose levels, especially in diabetic patients. - Drug interactions: review concomitant medications that may affect metabolism. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nilotinib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce nilotinib exposure. - Proton‑pump inhibitors (e.g., omeprazole) taken with nilotinib: decrease absorption and efficacy. - QT‑prolonging agents (e.g., certain antiarrhythmics): increase risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): may require INR monitoring. - Statins metabolized by CYP3A4 (e.g., simvastatin): risk of increased statin levels. - Antidiabetic drugs: nilotinib can affect glucose control, requiring dose adjustments.